← Back to Search

Small Molecule

VTX2735 for Periodic Syndrome (Explore Trial)

Phase 2

Waitlist Available

Research Sponsored by Zomagen Biosciences, Ltd

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of CAPS and FCAS subtype and mild clinical phenotype

At least one flare during screening/washout

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from day 1 to completion of treatment with vtx2735, up to day 28

Awards & highlights

Explore Trial Summary

This trial will test if VTX2735 is safe/effective for treating Cryopyrin-Associated Period Syndrome (CAPS) in 10 patients, over a max of 4 weeks.

Eligible Conditions

Cryopyrin-Associated Periodic Syndromes

Explore Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

You have been diagnosed with a specific subtype of a rare condition and have a mild form of the disease.

Select...

You have experienced at least one worsening of your condition during the screening period.

Explore Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from day 1 to completion of treatment with vtx2735, up to day 28

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from day 1 to completion of treatment with vtx2735, up to day 28

This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 to completion of treatment with vtx2735, up to day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety and Tolerability of VTX2735

Secondary outcome measures

Achievement of 30%, 50%, or 75% improvement in mean KSS from baseline

Maximum severity of any symptom score on DHAF2

Mean change in the mean key symptom score (KSS) derived from the Daily Health Assessment Form, Second Generation (DHAF2) from baseline

+2 more

Explore Trial Design

2Treatment groups

Experimental Treatment

Group I: Cohort 2Experimental Treatment1 Intervention

Group II: Cohort 1Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

VTX2735

2023

Completed Phase 2

~10

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Zomagen Biosciences, LtdLead Sponsor

Matt Cascino, MDStudy DirectorVentyx Biosciences, Inc

1 Previous Clinical Trials

205 Total Patients Enrolled

Media Library

VTX2735 (Small Molecule) Clinical Trial Eligibility Overview. Trial Name: NCT05812781 — Phase 2

Cryopyrin-Associated Periodic Syndromes Research Study Groups: Cohort 2, Cohort 1

Cryopyrin-Associated Periodic Syndromes Clinical Trial 2023: VTX2735 Highlights & Side Effects. Trial Name: NCT05812781 — Phase 2

VTX2735 (Small Molecule) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05812781 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How likely are individuals to experience adverse effects when participating in Cohort 1?

"Since Cohort 1 is currently being trialled in Phase 2, our team at Power has estimated its safety to be a score of 2. This rating indicates that there are data that support the drug's security, but no evidence indicating how effective it may be."

Answered by AI

Is recruitment for this research project still taking place?

"Affirmative, the information hosted on clinicaltrials.gov indicates that this research project is currently looking for participants. Initially posted on March 18th 2023, and recently updated in April 11th of the same year; 10 patients will be accepted from two specific locations."

Answered by AI

How many participants are engaged in this research?

"Affirmative. Information accessed via clinicaltrials.gov reveals that this research endeavour, which was originally posted on March 18th 2023, is currently enrolling participants. The investigation desires 10 patients to be recruited from 2 distinct medical facilities."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

2023. "A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05812781.